Averna Therapeutics
Jake Olin serves as the VP and Head of Business Development at Averna Therapeutics since April 2025. Prior to this role, Olin held the position of Sr. Director of Business Development at Orna Therapeutics from April 2022 to April 2025 and served as Director at Biogen from June 2020 to April 2022. Previous experience includes various director and managerial roles at Pfizer, including Sr. Manager of Oncology Business Development, and Corporate Development Manager at Teleflex Incorporated. Olin has also worked as a Consulting Associate at Charles River Associates and as a Consultant at Leerink Swann. Early career roles include Analyst in Investment Banking at Leerink Swann, Research position at Predictive Biosciences, and Research Assistant at Critical Therapeutics. Education includes a BA in Economics and Pre-Medicine from New York University, earned between 2004 and 2008.
This person is not in any teams
This person is not in any offices
Averna Therapeutics
Averna Therapeutics is a biotechnology company developing Ribonucleic acid (RNA) and lipid nanoparticle (LNP)-based genomic medicines to durably and safely treat a broad range of diseases, including genetic diseases, cancer, and autoimmune conditions. Our proprietary technology is based on a natural system and inserts therapeutic genetic instructions into “safe harbor” sites in the genome – genomic regions that allow stable gene integration without disrupting normal cell function. Because our medicines are encoded in RNA, they can be delivered using validated, non-viral delivery platforms that are safe, efficient, scalable, and cost-effective, and that allow redosing to effect with a curative intent. Follow us on LinkedIn and stay in touch as we seek to advance develop RNA/LNP-based genomic medicines that deliver meaningful solutions for patients!